Ozempic: Riesgos crecientes por uso estético sin supervisión médica

Regulatory agencies (FDA, international health bodies) face diminished enforcement capacity against uncontrolled pharmaceutical distribution via internet. Pharmaceutical companies lose control over drug use and reputation. Emerging markets experience regulatory gaps enabling counterfeit/impure products.

Similar to the opioid crisis trajectory: FDA-approved medication repurposed for non-medical use, inadequate regulatory oversight of distribution channels, delayed public health response despite mounting adverse event data, and disproportionate impact on populations with limited medical access.

Consumers face health risks from unsupervised use and counterfeit products; legitimate patients may experience supply constraints and price increases; potential for costly adverse event litigation and medical interventions for vision loss, muscle deterioration, and gastrointestinal complications.

Likely regulatory tightening including stricter prescription controls, enhanced online pharmacy oversight, mandatory medical supervision requirements, potential import restrictions on counterfeit medications, increased FDA enforcement, and possible manufacturer liability expansion for off-label marketing.